Recombinant human VEGF superagonist

Recombinant human VEGF superagonist refers to a modified version of Vascular Endothelial Growth Factor (VEGF) that exhibits enhanced agonistic activity compared to naturally occurring VEGF. VEGF is a crucial protein involved in angiogenesis, the formation of new blood vessels, and vasculogenesis. It plays vital roles in physiological processes such as wound healing, embryonic development, and regulating blood vessel permeability. A superagonist version would bind to and activate VEGF receptors (VEGFR1 and VEGFR2) with greater potency, potentially leading to a stronger pro-angiogenic effect. While recombinant human VEGF (specifically isoforms like VEGF-A/VEGF165) is widely produced by various companies for research purposes, a specific therapeutic drug explicitly named "Recombinant human VEGF superagonist" does not appear to be a commonly recognized or marketed pharmaceutical product. Instead, the term describes a functional characteristic of a recombinant VEGF protein designed for enhanced activity. Such a molecule would likely be investigated for conditions requiring increased blood vessel formation, such as ischemic diseases or wound repair.